All In Biotech

Drug Trial Radar · NCT07807007

Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma

A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Active-Controlled, Multicenter Phase II Study to Evaluate the Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Nov 21, 2025

Primary completion

Aug 3, 2026

Study completion Aug 17, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate whether two different doses of an investigational drug (CP006 Inhalation Powder, a triple combination of budesonide, formoterol, and umeclidinium) improve lung function in adults with asthma compared to an active comparator (budesonide/formoterol inhalation powder, a marketed two-component product). The main questions it aims to answer are: Does CP006 produce a greater change in lung function (measured by trough FEV₁ before morning dose) after 28 days of treatment compared to the comparator? What medical problems do participants experience when taking CP006? Researchers will compare two dose levels of CP006 against the active comparator in a 1:1:1 ratio. Participants will: Complete a screening visit (up to 7 days) to confirm eligibility, including medical history, physical exam, and lung function tests Enter a 14-day run-in period during which they take the comparator medication (budesonide/formoterol) twice daily Be randomly assigned to one of three treatment groups: CP006 Dose 1, CP006 Dose 2, or the comparator Take their assigned treatment twice daily for 28 days Visit the clinic at Day 0 (baseline), Day 8, Day 15, and Day 29 for lung function tests, safety checks, and questionnaires (ACQ-5 and AQLQ) Measure their morning and evening peak expiratory flow (PEF) daily using a handheld device and record the results in a diary Return for a follow-up safety visit or phone call at Day 43 (±2 days) The total duration of participation is approximately 58 to 65 days.

Conditions

  • Asthma

Interventions

  • Budesonide, Formoterol Fumarate, and Umeclidinium BromideDrug

    CP006 Inhalation Powder, 195 μg/5.5 μg/27.5 μg per inhalation. Administered as 1 inhalation twice daily for 28 days. Contains budesonide 195 μg, formoterol fumarate 5.5 μg, and umeclidinium bromide (equivalent to umeclidinium 27.5 μg) per inhalation.

  • Budesonide, Formoterol Fumarate, and Umeclidinium BromideDrug

    CP006 Inhalation Powder, 195 μg/5.5 μg/13.8 μg per inhalation. Administered as 1 inhalation twice daily for 28 days. Contains budesonide 195 μg, formoterol fumarate 5.5 μg, and umeclidinium bromide (equivalent to umeclidinium 13.8 μg) per inhalation.

  • Budesonide and Formoterol FumarateDrug

    Budesonide and formoterol fumarate inhalation powder (Symbicort® Turbuhaler®), 160 μg/4.5 μg per inhalation. Administered as 2 inhalations twice daily for 28 days.

  • Placebo for CP006 Inhalation PowderDrug

    Placebo matching CP006 Inhalation Powder. Contains no active pharmaceutical ingredients. Administered as 1 inhalation twice daily for 28 days to maintain blinding.

  • Placebo for Budesonide and Formoterol FumarateDrug

    Placebo matching budesonide and formoterol fumarate inhalation powder (Symbicort® Turbuhaler®). Contains no active pharmaceutical ingredients. Administered as 2 inhalations twice daily for 28 days to maintain blinding.

  • Albuterol SulfateDrug

    Albuterol sulfate inhalation aerosol (Ventolin®), 100 μg per actuation. Used as rescue medication on an as-needed basis for asthma symptoms during the run-in and treatment periods.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Morning Pre-dose Trough FEV₁ at Day 29Time frame: Baseline (Day 0) and Day 29

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Hefei First People's Hospital

    Hefei, Anhui, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Chongqing Fuling Central Hospital

    Chongqing, Chongqing Municipality, China

  • Gansu Provincial Hospital

    Lanzhou, Gansu, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China

  • Huai'an First People's Hospital

    Huai'an, Jiangsu, China

  • Lianyungang First People's Hospital

    Lianyungang, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Yan'an University Xianyang Hospital

    Xianyang, Shaanxi, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • Zhongjiang People's Hospital

    Kaijiang, Sichuan, China

  • Mianyang Central Hospital

    Mianyang, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.